Method of individual psychologic rehabilitation of patients with prosthetic heart valves. RU patent 2444288.

FIELD: medicine.

SUBSTANCE: invention relates to medicine, cardiology and cardiac surgery, and can be used for psychological rehabilitation of patients with prosthetic heart valves (PHV). Method includes studying index of development of anxious disorders in pre-operational and post-operational periods and carrying out procedures for patients who have undergone cardiosurgical operations, including drug therapy. In determination of anxiety higher level is considered to be from 31 points and higher, additionally performed are point massage and muscular relaxation successively with groups of muscles of arms, forearms, face, neck, shoulder girdle, abdomen, hips, ankles and feet. Relaxation with each group of muscles is performed for 5-10 seconds 2-3 times per week.

EFFECT: method improves results of treatment of patients with PHV due to complex impact taking into account reactive and personality anxiety.

1 tbl

IPC classes for russian patent Method of individual psychologic rehabilitation of patients with prosthetic heart valves. RU patent 2444288. (RU 2444288):

A61P25/22 - Anxiolytics

A61K31/5513 -

A61H39 - Devices for locating or stimulating specific reflex points of the body for physical therapy, e.g. acupuncture (locating by bioelectric signal detection A61B0005040000; locating by using electric currents or magnetic fields A61B0005050000)

A61H1 - PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY (electrotherapy, magnetotherapy, radiation therapy, ultrasound therapy A61N)

A61B5/16 - Devices for psychotechnics (using teaching or educational appliances G09B0001000000-G09B0007000000); Testing reaction times

Another patents in same IPC classes:

Composition for injections based on crystalline β-modification of 7-brom-1,3-dihydro-5-(2-chlorphenyl)-2h-1,4-benzodiazepin-2-one exhibiting tranquilising action and method for preparing it / 2440120
Group of inventions relates to medicine, in particular to pharmacy. A composition for injections exhibiting tranquilising action contains the ingredients in the following proportions, wt %: crystalline β-modification of 7-brom-1,3-dihydro-5-(2-chlorphenyl)-2H-1,4-benzodiazepin-2-one - 0.05-0.15, polyvinylpyrrolidone - 0.50-1.20, "Tween-80" - 2.00-10.00, glycerine - 5.00-15.00, sodium pyrosulphite - 0.30-1.20, sodium hydrate solution - to pH 6.0-7.5, water - the rest. A method for preparing the composition consist in the fact that "Tween-80" and glycerine are mixed, heated to 70-90°C, and crystalline β-modification of 7-brom-1,3-dihydro-5-(2-chlorphenyl)-2H-1,4-benzodiazepin-2-one is dissolved. The prepared mixture is poured in the mixed aqueous solution of sodium pyrosulphite and polyvinylpyrrolidone heated to 40-90°C, cooled to room temperature, filtered, reduced to pH 6.0-7.5 with sodium hydrate solution, bottled and sterilised.

Mglur5 modulators / 2439068
Described are novel compounds of general formula I:

Agent showing serotonin 5-ht<sub>3</sub>-receptor antagonist properties

Agent showing serotonin 5-ht₃-receptor antagonist properties / 2438669
What is offered is a biologically active substance showing 5-HT3-serotonin receptor antagonist properties, 1-piperidinopropyl-2-(4-fluorophenyl)imidazo[1,2-a]benzimidazole of formula I. The compound has been known as a local anaesthetic. There are shown evident 5-HT3-antagonist properties of the compound in the macromolar concentration equal to the reference preparation ondansetron with the compound of formula I being safer.

Medication possessing antidepressive, anxiolytic and nootropic action / 2437659
Invention relates to pharmaceutical industry and medicine. Claimed is application of N-carbamoyl-4-(n-methoxyphenyl)-2-pyrrolidone of structural formula as means possessing antidepressive, anxiolytic and nootropic action. This low-toxic compound (LD50 2263.88 mg/kg) possesses high antidepressive, anxiolytic and nootropic activity, affect of which is not accompanied by hypnosedative phenomena, or reduction of mental and physical work ability.

Thiophenyl and pyrrolyl azepines as serotonin 5ht<sub>2c</sub> receptor ligands and use thereof

Thiophenyl and pyrrolyl azepines as serotonin 5ht_2c receptor ligands and use thereof / 2434872
Invention relates to compounds of formula , where X denotes S; R1 and R2 taken together with atoms to which they are bonded form a 5-member carbocycle, substituted with up to two substitutes selected from alkyl and CF3; R3 is selected from a group consisting of a hydrogen atom and C1-8-alkyl; R3a denotes a hydrogen atom; R4 denotes a hydrogen atom; R4a denotes a hydrogen atom; R5 denotes a hydrogen atom; R5a denotes a hydrogen atom; R6 denotes a hydrogen atom; R6a denotes a hydrogen atom; R7 denotes a hydrogen atom; or pharmaceutically acceptable salts thereof. The invention also relates to compounds of the given formula, compounds selected from the group, as well as a pharmaceutical composition.

Crystalline beta-modification of 7-bromo-1,3-dihydro-5-(2-chlorophenyl)-2h-1,4-benzodiazepin-2-one and synthesis method thereof / 2430094
Described is a novel crystalline β-modification of 7-bromo-1,3-dihydro-5-(2-chlorophenyl)-2H-1,4-benzodiazepin-2-one (phenazepam) and synthesis method thereof, which can be used in pharmaceutical industry and medicine as a tranquilliser. Said novel crystalline β-modification of 7-bromo-1,3-dihydro-5-(2-chlorophenyl)-2H-1,4-benzodiazepin-2-one is characterised by certain interplanar spacing (A0) and corresponding intensity and parameters of the crystal lattice, given in the claims.

S-adenosylmethionine compositions for peroral application / 2427376
Claimed are dietary and/or nutriceutic pharmaceutical composition for peroral application which contains S-adenosylmethi-onine-para-toluolsulfonate (SAMe) in combination with inositol and/or ino-sitol-1-phosphate and pharmaceutically acceptable excipients, in which at least one of and pharmaceutically acceptable excipients represents magnesium oxide in concentration from approximately 1.0 to approximately 10.0% of composition weight (versions), method of its obtaining, method of stabilisation of hard food and/or nutriceutic pharmaceutical composition based on SAMe-para-toluolsulfonate by application of inositol and/or inositol-1-phosphate, application of SAMe-para-toluolsulfonate in combination with inositol and/or inositol-1-phosphate for obtaining composition for treatment of depressive states and panic syndromes.

Alkyl sulphonamide quinolines with affinity to nk-3 receptors / 2421447
Compound is ((S)-1-phenyl-propyl)-amide 3-(methane sulphonyl amino)-2-phenyl- quinoline-4-carboxylic acid, stereoisomer, enantiomer or pharmaceutically acceptable salt thereof. The invention also relates to a pharmaceutical composition based on the disclosed compound.

Polymorphic modification in n-{5-[3-(thiophene-2-carbonyl)-pyrazolo[1,5-a]pyrimidin-7-yl]-2-fluoro-phenyl}-n-methyl-acetamide (versions), containing it pharmaceutical composition (versions), medication, method of obtaining said polymorphic modification (versions) and method of treatment and/or prevention of nervous disorders / 2413729
Claimed invention describes novel polymorphic modification N-{5-[3-(thiophene-2-carbonyl)-pyrazolo[1,5-a]pyrimidin-7-yl]-2-fluoro-phenyl}-N-methyl-acetamide, methods of its obtaining, its application as medication, its application for preparation of medication and pharmaceutical compositions, including novel polymorphic modification.

Anti-vomit nk-1 antagonist metabolites / 2404969
Invention relates to compounds of general formula (I) , where R is methyl and R1 is 4-methyl-oxy-piperazin-1-yl; or R is CH2OH and R1 is 4-methyl-piperzin-1-yl or 4-methyl-4-oxy-piperazin-1-yl; and to pharmaceutically acceptable acid addition salts thereof, as well as to a medicinal agent based on said compounds, having NK-1 receptor antagonist activity and to use of said compounds in treating NK-1 receptor associated diseases.

Method for metabolic syndrome correction in schizophrenic patients / 2432162
Invention refers to medicine, namely to psychiatry, and concerns treating metabolic syndrome in schizophrenic patients. That is ensured by integrated treatment including rhythmic motions for an hour 3 times a week throughout 6 months combined with introduction of neuroleptics. The second generation neuroleptics are replaced by first generation neuroleptics according to the developed scheme with considering prevailing semiology in a specific patient.

2,4-di(aminophenyl)pyrimidines as plk-kinase inhibitors / 2404979
Invention refers to new compounds exhibiting antiproliferative activity of formula (1) where W means N or C-R2; X means -NH-; Y means CH; Z means halogen, -NO2, C2-C3alkynyl-, halogen-C1-C3alkyl- and -C(=O)-C1-C3alkyl, A means a group of formula (i), (ii) or (iii) Q1 means phenyl; B1, B2, B3 and B4 independently mean C-RgRh, N-Ri or O; R1 means hydrogen; R2 means a residue specified from the group including hydrogen, halogen and -OR4; Ra, Rb, Rc, Rd, Re and Rf independently mean hydrogen; Rg and Rh independently mean a residue specified from the group including hydrogen, =O, -OR4 and -NR4C(=O)R5; or mean optionally a residue monosubstituted or twice-substituted with equal or different substitutes and specified from the group including C1-C6alkyl and phenyl, the substitute/substitutes is/are specified from the group including R8/, -OR4, -C(=O)R4, -C(=O)OR4 and -C(=O)NR4R5 where R8/ and other values of radicals are specified in the patent claim, optionally in the form of their pharmacologically noncontaminating acid addition salts. The invention also concerns a pharmaceutical composition.

Method for treatment of drug-resistant epilepsy / 2404777
Invention relates to medicine, namely to dietology and neurology, and relates to treatment of drug-resistant epilepsy. For this purpose ketogenic dietary treatment is administered with monitoring of glucose level in blood and ketone bodies in urine. The first stage includes hungry phase with duration of not more than a day, which is interrupted as level of ketone bodies reaches 8-10 millimole/l or as glucose level in blood becomes lower than 3.5 millimole/l, independently on level of ketone bodies. At the second stage, high-fat cocktail is introduced during the day in three stages, having high ketogenic ratio of components. Then independently on level of ketone bodies, the third stage is started, including individual basis ketogenic food ration, at the same time, if therapeutic level of ketone bodies is not obtained at the first and second stages, at the third stage in daily ration 1-2 food intakes are substituted with high-fat cocktail, and in case ketonuria is not available in this case as well, basic food ration is recalculated with correction of its nutrition value.

Method of differential diagnostics of post-stroke affective disorders / 2391912
Invention relates to medicine, namely to nervous diseases. Strength of excitation processes and mobility of nervous processes are determined by J.Strelyau personality questionnaire. If strength of nervous processes in excitation is 42 points and higher, in nervous processes motility is 42 points and higher minimal day dose of antidepressants or psychotherapy is administered. If strength of nervous processes in excitation is lower than 42 points, motility of nervous processes lower than 42 points - maximal day dose of antidepressants in combination with psychotherapy is administered. If strength of nervous processes in excitation is lower than 42 points, motility of nervous processes is higher than 42 points maximal day dose of antidepressants in combination with psychotherapy is administered.

Pharmaceutical composition containing benzodiazepine derivatives and rsv fusion protein inhibitor / 2388476
Invention relates to pharmaceutics and concerns a pharmaceutical composition for treatment and prevention of respiratory syncytial virus (RSV) including the respiratory syncytial virus (RSV) fusion protein and a benzodiazepine derivative capable of inhibiting RSV replication.

Method for decrease in bone resorption / 2373939
Invention refers to medicine, namely to methods of osteogenesis regulation and stimulation, decrease in bone resorption. Tranquilisers are introduced in psychic tension to prevent intensification of bone resorption.

Therapy of inhibited paranoid preschizophrenia / 2364422
Invention refers to medicine, namely to psychiatry, and can be used for treatment of patients suffering from a first episode of schizophrenia. The therapy involves single session of plasmapheresis by discrete method on the first day. Starting from the second day within 40 days, diazepam 0.5% is injected intramuscularly in a dose 2-2.5 ml 3 times a day during 2 to 21 day and in the same dose twice a day in the following days, in combination with Mexidol in a daily dose 600-800 mg introduced intravenously drop-by-drop two-intake within 10-12 days, for the following 10 days intravenously drop-by-drop in a dose 300-400 mg two-intake and 250-375 mg orally tableted two-intake until termination of the therapy. Thymogen 0.01% is introduced in a dose 1-1.2 ml intramuscularly every second day, 15 injections totally. On the 30th day of treatment, single dose 35-40 mg of prolonged Fluanxol. Said pharmacotherapy is combined with hyperbaric oxygenation of excess pressure 0.8-1.0 atmosphere at compression and decompression rate 0.1 atmospheres per minute and isopression period 40 minutes twice a day within the first 20 days and once a day within the next 20 days.

Heterocyclic condensed compounds useful as antidiuretic agents / 2359969
Invention is related to the compound of general formula 1 or its tautomer or pharmaceutically acceptable salt, where W selected from N and CR4; X is selected from CH(R8), O, S, N(R8), C(=O), C(=O)O, C(=O)N(R8), OC(=O), N(R8)C(=O), C(R8)-CH and C(=R8); G1 - bicyclic or tricyclic condensed derivative of azepin, selected from general formulas 2-9 , or derivative of aniline of common formula 10 , where A1, A4, A7 and A10 are independently selected from CH2, C=O, O and NR10; A2, A3, A9, A11, A13, A14, A15, A19 and A20 are independently selected from CH and N; or A5 stands for covalent connection, and A6 represents S; or A5 stands for N=CH, and A6 represents covalent connection; A8 , A12 , A18 and A21 are independently selected from CH=CH, NH, NCH3 and S; A16 and A17 both represent CH2, or one from A16 and A17 represents CH2, and the one another is selected from C=O, CH(OH), CF2, O, SOc and NR10; Y is selected from CH=CH or S; R1 and R2 are independently selected from H, F, Cl, Br, alkyl, CF3 and group O-alkyl; R3 is selected from H and alkyl; R4-R7 are independently selected from H, F, Cl, Br, alkyl, CF3, OH and group O-alkyl; R8 is selected from H, (CH2)bR9 and (C=O)(CH2)bR9; R9 is selected from H, alkyl, possibly substituted aryl, possibly substituted heteroaryl, OH, groups O-alkyl, OC(=O)alkyl, NH2, NHalkyl, N(alkyl)2, CHO, CO2H, CO2alkyl, CONH2, CONHalkyl, CON(alkyl)2 and CN; R10 is selected from H, alkyl, group COalkyl and (CH2)dOH; R11 is selected from alkyl, (CH2)dAr, (CH2)dOH, (CH2)dNH2, group (CH2)aCOOalkyl, (CH2)dCOOH and (CH2)dOAr; R12 and R13 are independently selected from H, alkyl, F, CI, Br, CH(OCH3)2, CHF2, CF3, groups COOalkyl, CONHalkyl, (CH2)dNHCH2Ar, CON(alkyl)2, CHO, COOH, (CH2)dOH, (CH2)dNH2, N(alkyl)2, CONH(CH2)dAr and Ar; Ar is selected from possibly substituted heterocycles or possibly substituted phenyl; a is selected from 1, 2 and 3; b is selected from 1, 2, 3 and 4; c is selected from 0, 1 and 2; and d is selected from 0, 1, 2 and 3. Besides, the invention is related to pharmaceutical compound and to method for activation of vasopressin receptors of type 2.

Method of treating and increasing quality of patients with gallbladder dyskinesia / 2440807
Invention relates to medicine, namely to gastroenterology, physiotherapy, rexlexotherapy. Method includes carrying out drug therapy. Additionally, taking into account degree of expression of anxiety-depressive disorders by Hamilton scale data, antidepressant asaphen is introduced. In case of clinically expressed disorders asaphen is introduced in dose 75 mg per day, in case of subclinically expressed affective disorders - in dose 50 mg per day. Intake of asaphen is realised during 30 days. Taking into account individual peculiarities of vegetative balance state magnetic laser puncture is performed. For this purpose used is wavelength 1.3 mcm, modulated mode, frequency 2.4 Hz, magnetic-acupuncture nozzle 50 mT. Impact is carried out during 10-30 s per one biologically active point. In case of sympathicotonia point Gl 4 is sedated and points E 25, E 36, MC 6 are toned up. In case of vagotonia point Gl 4 is toned up and points E 25, E 36, MC 6 are sedated. Course includes 10-12 procedures.